| GTO ID | GTC2944 |
| Trial ID |
NCT05257083
|
| Disease |
Multiple Myeloma
|
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Carvykti|Ciltacabtagene Autoleucel|Cilta-cel|JNJ-68284528 |
| Co-treatment | Daratumumab, Bortezomib, Lenalidomide, Dexamethasone |
| Location approved | US, EU, UK, Japan, Australia, Canada |
| Generation | 2nd |
| Phase | Phase3 |
| Recruitment status | Not Recruiting |
| Title | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma |
| Year | 2022 |
| Country | Switzerland |
| Company sponsor | European Myeloma Network |
| Other ID(s) | EMN28/68284528MMY3005|2021-003284-10 |